Free tool
FAERS Monitor: Firdapse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208078 or its brand name (Firdapse, Amifampridine Phosphate). Reports on generic versions are filed under their own applications.
Reports
2,964
Serious
1,591
54% of reports
Hospitalization
806
Death reported
216
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthenia379
- drug ineffective357
- paraesthesia347
- paraesthesia oral281
- fall258
- condition aggravated223
- fatigue217
- nausea210
- muscular weakness204
- headache191
- diarrhoea177
- dizziness175
- dyspnoea168
- off label use164
- product dose omission issue164
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 379 |
| 2020 | 253 |
| 2021 | 273 |
| 2022 | 171 |
| 2023 | 368 |
| 2024 | 289 |
| 2025 | 537 |
| 2026 | 681 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,195 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paraesthesia oralSignal | 281 | 141.0 | 126.0 | 38,179 |
| paraesthesiaSignal | 347 | 15.7 | 14.2 | 4,781 |
| muscular weaknessSignal | 204 | 12.8 | 11.2 | 2,207 |
| astheniaSignal | 379 | 7.2 | 6.5 | 2,036 |
| fallSignal | 258 | 5.5 | 4.9 | 961 |
| condition aggravatedSignal | 223 | 5.2 | 4.6 | 764 |
| product dose omission issueSignal | 164 | 4.0 | 3.4 | 365 |
| dizzinessSignal | 175 | 2.5 | 2.2 | 158 |
| headacheSignal | 191 | 2.2 | 1.9 | 122 |
| dyspnoeaSignal | 168 | 2.1 | 1.8 | 99 |
| fatigue | 217 | 2.0 | 1.7 | 108 |
| diarrhoea | 177 | 1.9 | 1.7 | 83 |
| drug ineffective | 357 | 1.9 | 1.7 | 168 |
| nausea | 210 | 1.9 | 1.7 | 89 |
| off label use | 164 | 1.3 | 1.1 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.